menu
    • menu
    [{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synendos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Synendos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Ysios Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Synendos Therapeutics

    Menu

    Synendos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, S...

                            Details : SYT-510 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 01, 2024

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synendos Therapeutics AG Granted EMA Authorization for SYT-510 Clinical Trial

                            Details : SYT-510, a first-in-class inhibitor, targets the Endocannabinoid System to restore healthy brain function. It is being studied in preclinical trials for anxiety, PTSD, and mood-related disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Ysios Capital

                            Deal Size : $26.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Synendos Therapeutics Expands Series A to CHF 24 Million with New Investment

                            Details : This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 20, 2021

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Ysios Capital

                            Deal Size : $26.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Synendos Therapeutics

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Kurma Partners

                            Deal Size : $22.4 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Synendos Therapeutics Raises CHF 20 Million in Series A Financing

                            Details : Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 12, 2020

                            Lead Product(s) : SYT-510

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Kurma Partners

                            Deal Size : $22.4 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth